Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.49 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022110 | 1.00 | KDM4E (0.50) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL6820246 | 0.88 | EIF2AK4 (0.60) | KDM4EALDH1A1HSD17B10GPBAR1EIF2AK4 | |
| SCHEMBL23582548 | 0.84 | HRH3 (0.52) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL23582547 | 0.84 | HRH3 (0.52) | KDM4EMEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL14810701 | 0.83 | LMNA (0.57) | KDM4EHSD17B10NOTUMTRPV1 | |
| SCHEMBL12185358 | 0.82 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10GPBAR1TSHR | |
| SCHEMBL2635948 | 0.82 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10GPBAR1TSHR | |
| SCHEMBL29438234 | 0.82 | ALDH1A1 (0.54) | KDM4EALDH1A1HSD17B10GPBAR1TSHR | |
| SCHEMBL28810434 | 0.81 | EIF2AK4 (0.54) | EIF2AK4HSD11B1 | |
| SCHEMBL28810433 | 0.81 | EIF2AK4 (0.54) | EIF2AK4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| CN-114846013-B | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2024-12-20 | — | — | CN | disclosed |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4206193-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-116056706-A | Novel biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2023-05-02 | — | — | CN | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4071147-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021133035-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2021-07-01 | — | — | WO | disclosed |
| EP-2600874-B1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011143033-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | DCK, DTYMK, TYMS | KDM4E 822/4885MEN1 3186/4885ALDH1A1 725/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | KDM4E 1486/4885MEN1 4725/4885ALDH1A1 480/4885 |
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | KDM4E 2552/4885MEN1 4609/4885ALDH1A1 600/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | KDM4E 2839/4885MEN1 4788/4885ALDH1A1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.